GLUE compared with SVRA: revenue, margins and what each company keeps, and the suppliers and customers both name

GLUEMonte Rosa Therapeutics, Inc.

Mkt capRevenueRevenue

SVRASavara Inc

Mkt capRevenueRevenue

Compare

GLUEMonte Rosa Therapeutics, Inc.

SVRASavara Inc

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Supply-chain overlap

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Supply-chain overlap

direct ties · both sidesSources ›

direct ties · both sides

Only GLUE 0

None

Shared 0

No disclosed counterparties: GLUE.

Only SVRA 7

—FUJIFILM Diosynth Biotechnologiesunlistedsupplier

—GEMA Biotechunlistedsupplier

—Parexelunlistedsupplier

—PARI Pharma GmbHunlistedsupplier

3 more · SVRA chain ›

Role chip = supplier or customer—= no ticker (unlisted)Source: SEC EDGAR

GLUEMonte Rosa Therapeutics, Inc.

10.57▲+3.09%· post 10.57

Mkt cap$875.9MRevenue$54MQ3 FY26Revenue$124MFY25

SVRASavara Inc

4.83▲+10.27%· post 4.84

ClosedNov 6 '26

Mkt cap$992.4MRevenue—Revenue—

Compare

ClosedNov 6 '26

GLUEMonte Rosa Therapeutics, Inc.

SVRASavara Inc

10.57▲+3.09%post 10.57

Price

4.83▲+10.27%post 4.84

$875.9M

Mkt cap

$992.4M

Q3 FY26$54M

Revenue

—

FY25$124M

Revenue

—

GLUE10.57▲+3.09%vsSVRA4.83▲+10.27%ClosedNov 6 '26